Randomized Phase II Study of a Combination of Cisplatin (DDP), 5-Fluorouracil (5-FU), and Allopurinol (HPP) Versus 5-FU in Advanced Colorectal Carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study
作者:
BleibergHarry,
VanderlindenBernard,
BuyseMarc,
HaegeleP.,
PaillotBernard,
TagnonAlain,
WilsJacques,
CarteiGuiseppe,
FornasieroAlberto,
DuezNicole,
期刊:
Cancer Investigation
(Taylor Available online 1990)
卷期:
Volume 8,
issue 5
页码: 471-475
ISSN:0735-7907
年代: 1990
DOI:10.3109/07357909009012070
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractIn order to improve the therapeutic index of fluorouracil (5-FU), it has been combined with cisplatin (DDP) as synergistic agent and with allopurinol (HPP) as toxicity modulator. Patients with measurable colorectal carcinoma, previously untreated by chemotherapy, were randomized to receive either 5-FU alone 500 mg/m2push iv days 1–5 or HPP 3 300 mg po, days 1–5, 5-FU 800 mg/m2push iv, days 3–5 and DDP 50 mg/m2d6. Treatment was repeated every 4 weeks. Of 104 patients randomized, 82 were evaluable for response and survival. Six partial responses were seen in each treatment group (15%) and the median survival time was 7 months. Hematologic toxicities were comparable in both treatment groups, with a mean nadir white blood cell count of 3500/ vs. 3800/mm3and a mean nadir platelet count of 148,000/ vs. 203,000/mm3for HPP-5-FU-DDP and 5-FU, respectively. This study suggests that the addition of both HPP and DDP does not improve the activity of 5-FU.
点击下载:
PDF (307KB)
返 回